Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached...
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached...
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives...
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the...
Panel to take place on Monday, February 28, 2022, at 2:55pm EST / 11:55am PSTSAN DIEGO, Feb. 23, 2022 (GLOBE...
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairmentCAMBRIDGE, Mass. and...
Company’s partnership with Mighty Oak Medical for 3D printed, patient-specific technology continues advancing pediatric scoliosis treatmentWARSAW, Ind., Feb. 23, 2022...
-- INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BATON ROUGE, La., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health,...
Best corrected visual acuity and central subfield thickness were significantly improved at 36 monthsILUVIEN treatment resulted in a 70.5% reduction...
New Capabilities Allow 22nd Century to Accelerate Revenue Streams and Create Higher Value Commercial LinesBUFFALO, N.Y., Feb. 23, 2022 (GLOBE...
Highlights: Final three subjects in cohort three have been intravenously dosed; RECCE® 327 at 500mg indicating to be safe and...
Results Distinguish Deep TMS as More Effective in Subjects with Higher Anxiety Symptoms, Long Considered Less Responsive to Alternative TreatmentsBURLINGTON,...
MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up...
State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in Waltham, Massachusetts expected to...
Interim Results expected mid-2022REHOVOT, Israel and WILMINGTON, Del., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a...
VANCOUVER, British Columbia,, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the “Company” or “Simply Better Brands” or...
Staffed by a Highly Experienced Team of Licensed Hearing Professionals and Leading Salespeople from Competitor PlatformsAims to Enhance Customer Experience...